412
Participants
Start Date
October 24, 2017
Primary Completion Date
January 8, 2018
Study Completion Date
March 13, 2018
HTX-011
HTX 011 (bupivacaine/meloxicam), 60 mg/1.8 mg by instillation
Saline Placebo
Saline placebo by instillation
Bupivacaine HCl
Bupivacaine HCl without epinephrine, 50 mg by injection
Luer-lock applicator
Applicator for instillation
Vial access device
Device for withdrawal of drug product
Chesapeake Research Group, LLC, Pasadena
Springhill Medical Center, Mobile
Plano Surgical Hospital, Plano
Hermann Drive Surgical Hospital, Houston
Westside Surgical Hospital, Houston
Endeavor Clinical Trials, San Antonio
Futuro Clinical Trials, LLC, McAllen
Optimal Research , LLC, Austin
EPIC Medical Research, LLC, Murray
Jean Brown Research, Salt Lake City
Arizona Research Center, Phoenix
Orthopaedic Specialists of North America, PLLC, Mesa
Alliance Research Centers, Laguna Hills
Anaheim Clinical Trials, LLC, Anaheim
Trovare Clinical Research, Inc., Bakersfield
Lead Sponsor
Heron Therapeutics
INDUSTRY